CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

dupilumab

Last Updated: April 6, 2021
Result type: Reports
Project Number: SR0682-000
Product Line: Reimbursement Review

Generic Name: dupilumab

Brand Name: Dupixent

Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.

Therapeutic Area: atopic dermatitis, pediatrics

Indications: Dupixent (dupilumab injection) is indicated for the treatment of patients aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT® can be used with or without topical corticosteroids.

Manufacturer Requested Reimbursement Criteria1: Dupixent (dupilumab injection) is indicated for the treatment of patients aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: April 6, 2021

Call for patient/clinician input closed: April 23, 2021

Anticipated Date: April 21, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback